Smith & Nephew (SNN) agrees to acquire Healthpoint Biotherapeutics for $782M, allowing the...


Smith & Nephew (SNN) agrees to acquire Healthpoint Biotherapeutics for $782M, allowing the British medical products manufacturer to expand into the wound therapy sector. SNN expects the acquisition to exceed its cost of capital in the third full year following acquisition, to be broadly EPSA neutral in 2013 and accretive thereafter.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs